Abstract

Background and purpose: Although patients with esophageal squamous cell carcinoma (ESCC) can achieve a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) followed by surgery, one-third of these patients with a pCR may still experience recurrence. The aim of this study is to develop and validate a predictive model to estimate recurrence-free survival (RFS) in those patients who achieved pCR.Materials and methods: Two hundred six patients with ESCC were enrolled and divided into a training cohort (n = 146) and a validation cohort (n = 60). Radiomic features were extracted from contrast-enhanced computed tomography (CT) images of each patient. Feature reduction was then implemented in two steps, including a multiple segmentation test and least absolute shrinkage and selection operator (LASSO) Cox proportional hazards regression method. A radiomics signature was subsequently constructed and evaluated. For better prediction performance, a clinical nomogram based on clinical risk factors and a nomogram incorporating the radiomics signature and clinical risk factors was built. Finally, the prediction models were further validated by calibration and the clinical usefulness was examined in the validation cohort to determine the optimal prediction model.Results: The radiomics signature was constructed using eight radiomic features and displayed a significant correlation with RFS. The nomogram incorporating the radiomics signature with clinical risk factors achieved optimal performance compared with the radiomics signature (P < 0.001) and clinical nomogram (P < 0.001) in both the training cohort [C-index (95% confidence interval [CI]), 0.746 (0.680–0.812) vs. 0.685 (0.620–0.750) vs. 0.614 (0.538–0.690), respectively] and validation cohort [C-index (95% CI), 0.724 (0.696–0.752) vs. 0.671 (0.624–0.718) vs. 0.629 (0.597–0.661), respectively]. The calibration curve and decision curve analysis revealed that the radiomics nomogram outperformed the other two models.Conclusions: A radiomics nomogram model incorporating radiomics features and clinical factors has been developed and has the improved ability to predict the postoperative recurrence risk in patients with ESCC who achieved pCR after nCRT followed by surgery.

Highlights

  • Esophageal cancer (EC) is the fourth most prevalent cancer in China, has a poor prognosis and is the sixth leading cause of death worldwide [1, 2]

  • 15–30% of all patients with EC treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery achieve a pathological complete response [7,8,9] and ∼45% of patients with Esophageal squamous cell carcinoma (ESCC) achieve pCR [7, 10, 11], where pCR is defined as no histological evidence of the tumor in the surgical specimen

  • We aimed to develop and validate a radiomics signature-based model using the pretreatment computed tomography (CT) images to estimate recurrence-free survival (RFS) in patients with ESCC who achieved pCR after receiving nCRT followed by surgery

Read more

Summary

Introduction

Esophageal cancer (EC) is the fourth most prevalent cancer in China, has a poor prognosis and is the sixth leading cause of death worldwide [1, 2]. Esophageal squamous cell carcinoma (ESCC) is the most common subtype of esophageal malignancy and the cause of the highest morbidity in China compared to other developing countries [3, 4]. 15–30% of all patients with EC treated with nCRT followed by surgery achieve a pathological complete response (pCR) [7,8,9] and ∼45% of patients with ESCC achieve pCR [7, 10, 11], where pCR is defined as no histological evidence of the tumor in the surgical specimen. Patients with esophageal squamous cell carcinoma (ESCC) can achieve a pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) followed by surgery, one-third of these patients with a pCR may still experience recurrence. The aim of this study is to develop and validate a predictive model to estimate recurrence-free survival (RFS) in those patients who achieved pCR

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call